

A Comparative Study on The Efficacy of Low Dose 0.5% Bupivacaine and Fentanyl Versus Conventional Dose of Hyperbaric Bupivacaine Alone For Lower Segment Caesarean Section

Dr Abhishek Yesudhas^{1*}, Dr Sarvesh B², Dr U Anand Krishnan³

¹Junior Resident, Department of Anaesthesiology, Adichunchanagiri Institute of medical sciences & hospital, Adichunchanagiri University, B G Nagara, Nagamangala Taluk, Mandya District, Karnataka, India, abhiyesudas10@gmail.com

²Professor, Department of Anaesthesiology, Adichunchanagiri Institute of medical sciences & hospital, Adichunchanagiri University, B G Nagara, Nagamangala Taluk, Mandya District, Karnataka, India.

³Junior Resident, Department of Anaesthesiology, Adichunchanagiri Institute of medical sciences & hospital, Adichunchanagiri University, B G Nagara, Nagamangala Taluk, Mandya District, Karnataka, India.

Abstract

Background

Spinal anaesthesia is the preferred anaesthetic technique for Lower Segment Cesarean Section (LSCS). Conventional doses of hyperbaric bupivacaine provide effective surgical blocks but are frequently associated with a high incidence of maternal hypotension. This study evaluated whether a low-dose hyperbaric bupivacaine regimen combined with intrathecal fentanyl improves maternal hemodynamic stability while maintaining high-quality operative block characteristics and neonatal safety.

Methods

This prospective, randomized, double-blind clinical trial evaluated 60 American Society of Anesthesiologists (ASA) physical status II parturients undergoing elective LSCS. Participants were randomly allocated into two equal groups (n=30 each):

- Group B (Conventional-dose): Received 0.5% hyperbaric bupivacaine 1.8 mL (9.0 mg).
- Group BF (Low-dose adjuvant): Received 0.5% hyperbaric bupivacaine 1.6 mL (8.0 mg) combined with fentanyl 0.2 mL (10 mcg) intrathecally.

The primary outcomes included sensory and motor block characteristics and postoperative analgesia duration. Secondary outcomes evaluated intraoperative hemodynamic stability, maternal adverse event profiles, and neonatal Apgar scores.

Results

Parturients in Group BF achieved significantly faster sensory onset times to both the T10 and T6 dermatomes compared to Group B ($p = 0.002$ and $p = 0.033$, respectively). The overall duration of effective sensory blockade (96.00 ± 10.59 min vs. 82.53 ± 15.40 min; $p < 0.001$) and total postoperative analgesia duration (239.27 ± 40.69 min vs. 171.07 ± 30.58 min; $p < 0.001$) were significantly prolonged in the low-dose fentanyl group.

Hemodynamically, Group BF exhibited superior stability, demonstrating a significantly lower incidence of maternal hypotension (20.0% vs. 46.7%; $p = 0.028$) and a reduced requirement for therapeutic vasopressor support (16.7% vs. 40.0%; $p = 0.045$) with lower total ephedrine consumption (0.82 ± 2.21 mg vs. 5.36 ± 8.07 mg; $p = 0.004$). Pruritus occurred exclusively in Group BF (20.0% vs. 0.0%; $p = 0.024$). Neonatal Apgar scores at 1 and 5 minutes were statistically comparable between the groups ($p > 0.05$).

Conclusion

A low-dose intrathecal bupivacaine regimen (8.0 mg) co-administered with 10 mcg of fentanyl provides reliable, rapid surgical anesthesia for Cesarean section while significantly mitigating maternal hypotension and vasopressor requirements, with the added benefit of extended early postoperative analgesia.

Keywords: Spinal anesthesia; Hyperbaric bupivacaine; Intrathecal fentanyl; Cesarean section; Maternal hypotension; Obstetric analgesia.

1. Introduction

Lower segment cesarean section (LSCS) is one of the most frequently performed surgical procedures worldwide, and the choice of anesthetic technique plays a pivotal role in ensuring maternal safety, neonatal well-being, and optimal surgical conditions. Over the past few decades, regional anesthesia—particularly spinal anesthesia (SA)—has emerged as the preferred anesthetic modality for cesarean delivery. Spinal anesthesia involves the administration of a local anesthetic agent into the subarachnoid space, producing sensory, motor, and sympathetic blockade of the lower abdomen and lower limbs. The simplicity of the technique, rapid onset of action, minimal drug requirement, and reliable anesthetic effect have contributed significantly to its widespread acceptance in

obstetric practice.

Compared with general anesthesia, spinal anesthesia offers several advantages in cesarean sections, including better maternal awareness, avoidance of airway manipulation, reduced risk of aspiration, and minimal transplacental drug transfer to the fetus. The technique provides excellent muscle relaxation, ensures rapid surgical readiness, and is associated with reduced maternal mortality and morbidity. Furthermore, spinal anesthesia is cost-effective and is associated with a lower incidence of neonatal depression and fewer systemic side effects, making it particularly suitable for obstetric patients. These benefits have established spinal anesthesia as the gold standard anesthetic technique for both elective and emergency cesarean sections.

Several local anesthetic agents have been used for spinal anesthesia, including lidocaine, tetracaine, ropivacaine, and bupivacaine. Among these, bupivacaine—an amide-type local anesthetic—has become the most commonly used agent for spinal anesthesia in cesarean sections due to its long duration of action and favorable sensory-motor block profile. Bupivacaine is commercially available in both isobaric and hyperbaric forms, with hyperbaric bupivacaine being preferred for obstetric anesthesia because of its predictable spread and faster onset. Studies have shown that hyperbaric bupivacaine produces a more rapid onset of sensory blockade at the T4 dermatome level compared with isobaric bupivacaine, which is essential for achieving adequate anesthesia for cesarean delivery.

Despite its widespread use and advantages, spinal anesthesia is not devoid of limitations. One of the most common and clinically significant complications is post-spinal hypotension, which occurs due to sympathetic blockade resulting in vasodilation and decreased venous return. Maternal hypotension can lead to symptoms such as nausea, vomiting, dizziness, and, if severe, compromised uteroplacental perfusion, potentially affecting fetal oxygenation. Another drawback of spinal anesthesia is the relatively limited duration of postoperative analgesia when local anesthetics are used alone, often necessitating early administration of rescue analgesics.

To overcome these limitations, various adjuvants have been added to intrathecal local anesthetics to enhance the quality and duration of anesthesia and analgesia while minimizing adverse effects. Among these, neuraxial opioids such as fentanyl and morphine have been extensively studied and widely used. Fentanyl, a synthetic opioid belonging to the phenylpiperidine group, acts as a potent opioid receptor agonist with rapid onset and relatively short duration of action. These pharmacological properties make fentanyl a preferred intrathecal adjuvant in obstetric anesthesia.

Intrathecal fentanyl has been shown to enhance the analgesic efficacy of local anesthetics without significantly increasing the degree of motor blockade. It provides superior intraoperative analgesia, reduces visceral pain during uterine manipulation, and prolongs the time to first postoperative analgesic request. Additionally, fentanyl has a lower incidence of delayed respiratory depression compared with hydrophilic opioids such as morphine, making it safer for use in parturients. Doses ranging from 10 to 25 mcg of intrathecal fentanyl have been commonly employed as an additive to local anesthetics in spinal anesthesia for cesarean sections.

The addition of fentanyl to intrathecal bupivacaine has demonstrated several clinical advantages. These include reduced requirement for intraoperative supplemental analgesia, lower incidence of nausea and vomiting, improved patient comfort, and prolonged postoperative analgesia. Furthermore, the synergistic effect of fentanyl allows the use of a reduced dose of bupivacaine while maintaining adequate sensory blockade. This dose reduction has been associated with improved hemodynamic stability and a decreased incidence of post-spinal hypotension.

Clinical trials have evaluated the efficacy of fentanyl as an adjuvant to bupivacaine in spinal anesthesia for cesarean section and have reported favorable outcomes in terms of block quality and patient satisfaction. Recent studies suggest that the use of low-dose bupivacaine in combination with fentanyl can provide sufficient anesthesia while minimizing adverse hemodynamic effects. However, despite these promising findings, there remains no clear consensus regarding the optimal minimum dose of bupivacaine that can be safely and effectively used with fentanyl to achieve adequate anesthesia without compromising maternal or fetal safety.

The lack of standardized dosing protocols has led to variability in clinical practice, with anesthesiologists often relying on institutional preferences or personal experience. Determining an optimal low dose of bupivacaine combined with fentanyl could potentially reduce the incidence of hypotension, improve postoperative analgesia, and enhance overall maternal satisfaction, while maintaining adequate surgical anesthesia. This highlights the need for further well-designed clinical studies comparing low-dose bupivacaine combined with fentanyl against conventional doses of hyperbaric bupivacaine alone. In this context, the present study aims to evaluate and compare the anesthetic efficacy, hemodynamic stability, and analgesic profile of these two anesthetic regimens. By

assessing sensory and motor block characteristics, incidence of hypotension, and postoperative analgesia, this study seeks to contribute valuable evidence toward establishing an optimal spinal anesthesia regimen for cesarean section, thereby improving maternal and neonatal outcomes.

2. Methodology

2.1 Study Design & Population

This prospective, randomized, double-blind clinical study evaluated 60 ASA physical status II parturients undergoing elective LSCS at a tertiary care teaching hospital. Ethical clearance was obtained from the Institutional Ethics Committee, and written informed consent was collected from all participants.

2.2 Randomization & Blinding

Participants were randomly assigned to one of two parallel groups (n = 30 each) using a computer-generated random number sequence:

- Group B: Received 0.5% hyperbaric bupivacaine 1.8 mL (9.0 mg).
- Group BF: Received 0.5% hyperbaric bupivacaine 1.6 mL (8.0 mg) + fentanyl 0.2 mL (10 mcg). Identical syringes were prepared by an independent anesthesia technician to maintain strict double-blinding. Both the performing anesthesiologist and the investigator recording perioperative parameters remained blinded to group allocations.

2.3 Anesthetic Technique

All patients were pre-medicated and pre-loaded with Ringer's lactate solution (10-15 mL/kg). In the sitting or lateral position, lumbar puncture was performed at the L3-L4 or L4-L5 interspace using a standard Quincke spinal needle. Following confirmed free flow of cerebrospinal fluid (CSF), the study drug was injected over 15 seconds. Patients were immediately positioned supine with left uterine displacement to prevent aortocaval compression.

2.4 Outcome Measurements

Sensory block was assessed via pinprick every 2 minutes. Onset was defined as the time to reach the T10 and T6 dermatomes, and total sensory duration was recorded as the time to two-segment regression. Motor block was evaluated via the Modified Bromage Scale (0 = no block, 3 = complete block) until full motor function returned. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate (HR) were systematically recorded at baseline, 5, 10, 15, 20, 30, 45, 60, 80, and 100 minutes intraoperatively. Hypotension was defined as SBP < 90 mmHg or a > 20% decrease from baseline, managed with therapeutic intravenous ephedrine boluses. Neonatal well-being was documented using Apgar scores at 1 and 5 minutes.

2.5 Statistical Analysis

Continuous variables are expressed as Mean $\pm$ Standard Deviation (SD) and compared using the independent-samples student's t-test. Categorical and nominal variables are expressed as frequencies (percentages) and evaluated using the Chi-Square test or Fisher's Exact test as appropriate. Statistical significance was set at $p < 0.05$.

3. Results

3.1 Table 1. Maternal Demographic Data

Variable	Group B (n=30)	Group BF (n=30)	P value
Age (years)	27.67 $\pm$ 3.51	27.57 $\pm$ 2.92	0.905
BMI (kg/m ²)	27.07 $\pm$ 3.26	25.94 $\pm$ 3.22	0.183
ASA Status (II), n (%)	30 (100.0%)	30 (100.0%)	1.000

3.2 Table 2. Anesthetic Block and Analgesia Characteristics

Outcome Parameter	Group B (n=30)	Group BF (n=30)	P value
Time to T10 Sensory Onset (min)	3.90 $\pm$ 1.13	3.10 $\pm$ 0.81	0.002
Time to T6 Sensory Onset (min)	6.93 $\pm$ 1.91	5.91 $\pm$ 1.72	0.033

Maximum Sensory Height Achieved, n (%)			
* T4	11 (36.7%)	11 (36.7%)	1.000
* T6	16 (53.3%)	16 (53.3%)	
* T8	3 (10.0%)	3 (10.0%)	
Motor Block Onset (min)	4.84 ±1.37	3.96 ±0.89	0.004
Sensory Block Duration / Two-Segment Regression (min)	82.53 ±15.40	96.00 ±10.59	< 0.001
Total Motor Block Duration (min)	122.90 ±26.07	130.20 ±27.40	0.295
Postoperative Analgesia Duration (min)	171.07 ±30.58	239.27 ±40.69	< 0.001

3.3 Table 3. Hemodynamic Outcomes and Interventions

Variable	Group B (n=30)	Group BF (n=30)	P value
Lowest Intraoperative SBP (mmHg)	104.17 ± 10.69	112.93 ± 7.13	< 0.001
Lowest Intraoperative DBP (mmHg)	69.27 ±10.14	70.53 ± 9.13	0.265
Lowest Intraoperative MAP (mmHg)	80.93 ± 8.94	84.63 ± 6.73	0.021
Maximum Heart Rate Deviation (bpm)	82.10 ± 10.75	83.07 ± 10.53	0.726
Incidence of Maternal Hypotension, n (%)	14 (46.7%)	6 (20.0%)	0.028
Vasopressor Requirement (Yes), n (%)	12 (40.0%)	5 (16.7%)	0.045
Total Therapeutic Ephedrine Dose (mg)	5.357 ± 8.065	0.820 ± 2.208	0.004

3.4 Table 4. Complications and Adverse Event Profiles

Variable Outcome	Group B (n=30)	Group BF (n=30)	P value
Maternal Adverse Events, n (%)			
* Bradycardia	5 (16.7%)	2 (6.7%)	0.424
* Nausea	7 (23.3%)	3 (10.0%)	0.299
* Vomiting	4 (13.3%)	1 (3.3%)	0.353
* Pruritus	0 (0.0%)	6 (20.0%)	0.024
* Shivering	7 (23.3%)	4 (13.3%)	0.506
Neonatal Apgar Scores (Mean +/- SD)			
* Apgar at 1 min	7.90 ± 0.71	8.07 ± 0.58	0.325
* Apgar at 5 min	9.03 ± 0.41	9.10 ± 0.48	0.567

4. Discussion

The primary finding of this prospective, randomized, double-blind controlled trial is that decreasing the dose of intrathecal hyperbaric bupivacaine from 9.0 mg to 8.0 mg and co-administering 10 mcg of fentanyl significantly mitigates post-spinal maternal hypotension and subsequent vasopressor reliance during elective Cesarean delivery. Crucially, this local anesthetic dose reduction did not compromise the quality or speed of surgical block onset. Instead, it successfully prolonged the duration of effective early postoperative analgesia without impacting neonatal safety parameters, validating a clinical balance frequently sought in contemporary obstetric anesthesia.

The rapid sensory onset to the T10 and T6 levels observed in Group BF underscores the profound pharmacological synergism between local anesthetics and lipophilic opioid adjuvants in the subarachnoid space. Intrathecal fentanyl concentrates rapidly within the spinal cord dorsal horn, hyperpolarizing nociceptive neurons and suppressing afferent C and A-delta pain signals. This mechanism enhances the density and speed of the sensory blockade, compensating for a reduced mass of bupivacaine. This finding directly corresponds with the definitive trial by Ben-David et al. [43] and observations by Uppal et al., who demonstrated that low local anesthetic volumes supplemented with lipophilic opioids consistently achieve rapid, dense surgical block profiles.

Furthermore, our data confirms that limiting the hyperbaric bupivacaine mass to 8.0 mg curtails extensive cephalad sympathetic inhibition, which is the primary cause of sudden system-wide vasodilation and decreased

venous return in the supine parturient. This physiological preservation is reflected in the significantly higher blood pressure nadirs (SBP and MAP) observed in Group BF, resulting in a dramatic reduction in maternal hypotension from 46.7% to 20.0%. This protective hemodynamic benefit aligns closely with the landmark low-dose strategies popularized by Roofthoof and Van de Velde [40] and the large-scale systematic meta-analysis by Arzola and Wieczorek, which confirmed that minimizing bupivacaine dose fields reduces maternal circulatory collapse while ensuring surgical success.

Environmental stability and protection directly triggered a six-fold reduction in total vasopressor consumption within the adjuvant group (0.82 mg vs. 5.36 mg). In conventional practice, high-dose bupivacaine mandates aggressive, reactive titration of vasopressors like ephedrine to preserve maternal uterine blood flow. By minimizing this dependency, Group BF provides a safer profile for fluid-sensitive obstetric populations. This clinical advantage is strongly supported by Venkata et al., who similarly noted a drastic reduction in reactive vasopressor intervention when utilizing an identical low-dose bupivacaine-fentanyl mixture.

While the sensory block duration and time to first postoperative rescue analgesia request were significantly extended in Group BF, the overall duration of motor blockade remained statistically comparable to the conventional arm ($p = 0.295$). This is an ideal clinical endpoint. It facilitates early maternal mobilization and improves the overall recovery experience, mirroring findings by Sun et al. [44] and Baheti et al..

The primary clinical limitation linked to intrathecal fentanyl adjuvant use was a 20.0% incidence of mild, self-limiting maternal pruritus. This is a well-documented side effect triggered by the cephalad migration of opioid molecules interacting with mu receptors in the medullary dorsal horn, rather than systemic histamine release. This incidence aligns with rates reported across obstetric literature, and no cases in our cohort required pharmacological reversal or disrupted the surgical flow. Finally, neonatal safety remained uncompromised. Excellent, statistically equivalent 1-minute and 5-minute Apgar scores confirmed that a 10 mcg intrathecal dose does not achieve cross-placental concentrations capable of inducing neonatal respiratory or neurobehavioral depression, matching standard safety data established by Liu et al. [57] and Sun et al.

5. Conclusions

Co-administering 10 mcg of intrathecal fentanyl adjuvant with a reduced dose of hyperbaric bupivacaine (8.0 mg) provides safe spinal anesthesia for Cesarean delivery. It provides rapid block onset, superior maternal hemodynamic stability with lower vasopressor requirements, and significantly prolonged early postoperative pain relief without compromising neonatal outcomes.

6. References

1. Lumbiganon P, Moe H, Kamsa-Ard S, Rattanakanokchai S, Laopaiboon M, Kietpeerakool C, Jampathong N, Somjit M, Cecatti JG, Vogel JP, Betran AP. Outcomes associated with anaesthetic techniques for caesarean section in low-and middle-income countries: a secondary analysis of WHO surveys. *Scientific Reports*. 2020 Jun 23;10(1):10176.
2. Gee ME, Dempsey A, Myers JE. Caesarean section: techniques and complications. *Obstetrics, Gynaecology & Reproductive Medicine*. 2020 Apr 1;30(4):97-103.
3. Lim G, Facco FL, Nathan N, Waters JH, Wong CA, Eltzschig HK. A review of the impact of obstetric anesthesia on maternal and neonatal outcomes. *Anesthesiology*. 2018 Jul;129(1):192.
4. Majirija ET. Clinical Outcomes and Costs: A Comparison Between Spinal Anaesthesia and Intra-Venous General Anaesthesia for Emergency Caesarean Sections at a Regional Hospital in Swaziland. University of Pretoria (South Africa); 2013.
5. Gogarten W. Spinal anaesthesia for obstetrics. *Best practice & research Clinical anaesthesiology*. 2003 Sep 1;17(3):377-92.
6. Fedoruk KA, Sultan P. Obstetric anesthesia quality metrics: performance, pitfalls, and potential. *Anesthesia & Analgesia*. 2022 Mar 18:10-213.
7. Sun S, Wang J, Bao N, Chen Y, Wang J. Comparison of dexmedetomidine and fentanyl as local anesthetic adjuvants in spinal anesthesia: a systematic review and meta-analysis of randomized controlled trials. *Drug design, development and therapy*. 2017 Dec 1:3413-24.
8. Uppal V, Retter S, Casey M, Sancheti S, Matheson K, McKeen DM. Efficacy of intrathecal fentanyl for cesarean

delivery: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. *Anesthesia & Analgesia*. 2020 Jan 1;130(1):111-25.

9. Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK. A comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to bupivacaine. *Journal of anaesthesiology clinical pharmacology*. 2011 Jul 1;27(3):339-43.
10. Saleem S, Tariq T, Khan S, Khan IU. Comparative Study of Intra-operative Hemodynamic Changes During Cesarean Section Under Spinal Block by Using Bupivacaine Alone Versus Bupivacaine with Fentanyl. *Pakistan Journal of Medical & Cardiological Review*. 2026 Jan 30;5(1):388-93.
11. Yeoh SB, Leong SB, Heng AS. Anaesthesia for lower-segment caesarean section: Changing perspectives. *Indian journal of anaesthesia*. 2010 Sep 1;54(5):409-14.
12. Duggappa DR, Lokesh MP, Dixit A, Paul R, Rao RR, Prabha P. Perfusion index as a predictor of hypotension following spinal anaesthesia in lower segment caesarean section. *Indian journal of anaesthesia*. 2017 Aug 1;61(8):649-54.
13. Klimek M, Rossaint R, Van De Velde M, Heesen M. Combined spinal-epidural vs. spinal anaesthesia for caesarean section: meta-analysis and trial-sequential analysis. *Anaesthesia*. 2018 Jul;73(7):875-88.
14. Li M, Xie G, Chu L, Li Y. Efficacy of low-dose hypobaric anesthetics in spinal anesthesia for cesarean delivery: systematic review and meta-analysis. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2025 Dec 31;38(1):2519655.
15. Javed S, Hamid S, Amin F, Mahmood KT. Spinal anesthesia induced complications in caesarean section-A review. *Journal of Pharmaceutical Sciences and Research*. 2011 Oct 1;3(10):1530.
16. Hall PA, Bennett A, Wilkes MP, Lewis M. Spinal anaesthesia for caesarean section: comparison of infusions of phenylephrine and ephedrine. *British Journal of Anaesthesia*. 1994 Oct 1;73(4):471-4.
17. Dyer RA, Joubert IA. Low-dose spinal anaesthesia for caesarean section. *Current Opinion in Anesthesiology*. 2004 Aug 1;17(4):301-8.
18. Ng KW, Parsons J, Cyna AM, Middleton P. Spinal versus epidural anaesthesia for caesarean section. *Cochrane database of systematic reviews*. 2004(2).
19. Malinovsky JM, Charles F, Kick O, Lepage JY, Malinge M, Cozian A, Bouchot O, Pinaud M. Intrathecal anesthesia: ropivacaine versus bupivacaine. *Anesthesia & analgesia*. 2000 Dec 1;91(6):1457-60.
20. Deer TR, Serafini M, Buchser E, Ferrante FM, Hassenbusch SJ. Intrathecal bupivacaine for chronic pain: a review of current knowledge. *Neuromodulation: Technology at the Neural Interface*. 2002 Oct 1;5(4):196-207.
21. Buchser E, Durrer A, Chédel D, Mustaki JP. Efficacy of intrathecal bupivacaine: how important is the flow rate?. *Pain Medicine*. 2004 Sep 1;5(3):248-52.
22. Kee WN. Intrathecal pethidine: pharmacology and clinical applications. *Anaesthesia and intensive care*. 1998 Apr;26(2):137-46.
23. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. *Pain medicine*. 2011 Oct 1;12(10):1481-9.
24. Simpson RK. Mechanisms of action of intrathecal medications. *Neurosurgery Clinics*. 2003 Jul 1;14(3):353-64.
25. Naithani U, Saxena G, Jain S, Navaria R, Somani M, Negi A. Comparative evaluation of clinical efficacy and safety profiles of hyperbaric levobupivacaine versus hyperbaric bupivacaine in spinal anesthesia for lower segment cesarean section: A randomized double-blind study. *Journal of Obstetric Anaesthesia and Critical Care*. 2025 Jul 1;15(2):119-25.
26. Park SK, Lee JH, Yoo S, Kim WH, Lim YJ, Bahk JH, Kim JT. Comparison of bupivacaine plus intrathecal fentanyl and bupivacaine alone for spinal anesthesia with intravenous dexmedetomidine sedation: a randomized, double-blind, noninferiority trial. *Regional Anesthesia & Pain Medicine*. 2019 Apr 1;44(4):459-65.
27. Li B, Wang H, Gao C. Bupivacaine in combination with fentanyl or sufentanil in epidural/intrathecal analgesia for labor: A meta-analysis. *The Journal of Clinical Pharmacology*. 2015 May;55(5):584-91.
28. Hayek SM, Jones BA, Veizi E, Tran TQ, DeLozier SJ. Efficacy of continuous intrathecal infusion trialing with a mixture of fentanyl and bupivacaine in chronic low back pain patients. *Pain Medicine*. 2023 Jul 1;24(7):796-808.
29. Hamber EA, Viscomi CM. Intrathecal lipophilic opioids as adjuncts to surgical spinal anesthesia. *Regional anesthesia and pain medicine*. 1999 May 1;24(3):255-63.

30. Ramirez JP, Trujillo SG, Alcantarilla C. Intrathecal magnesium as analgesic adjuvant for spinal anesthesia: a meta-analysis of randomized trials. *Minerva Anestesiologica*. 2013;79:1-2.
31. Pascarella G, Ruggiero A, Garo ML, Strumia A, Di Folco M, Papa MV, Giacinto O, Lusini M, Costa F, Mattei A, Schiavoni L. Intrathecal dexamethasone as an adjuvant for spinal anesthesia: a systematic review. *Minerva anestesologica*. 2024;90(7-8):662-71.
32. Ollosu M, Tripodi VF, Bonu A, Cittadini G, Musu M, Ippolito M, Cortegiani A, Finco G, Sardo S. Efficacy and safety of intrathecal adjuvants for perioperative management of cesarean delivery: a systematic review and network meta-analysis of randomized controlled trials. *Regional Anesthesia & Pain Medicine*. 2025 Mar 26.
33. Qi X, Chen D, Li G, Huang X, Li Y, Wang X, Li Y. Comparison of intrathecal dexmedetomidine with morphine as adjuvants in cesarean sections. *Biological and Pharmaceutical Bulletin*. 2016 Sep 1;39(9):1455-60.
34. Yektas AK. Post-operative analgesic characteristics of intrathecal adjuvant agents including ketamine, fentanyl, sufentanyl, neostigmine, dexmedetomidine, midazolam and droperidol and their effects on spinal anesthesia. *Annals of Clinical and Laboratory Research*. 2019 Feb 20;7(01):1-7.
35. Karunarathna I. Fentanyl: clinical applications and pharmacological considerations. *Uva Clinical Lab*. 2024:1-6.
36. Jasinski T, Migon D, Sporysz K, Kamysz W, Owczuk R. The density of different local anesthetic solutions, opioid adjuvants and their clinically used combinations: an experimental study. *Pharmaceuticals*. 2021 Aug 16;14(8):801.
37. Arzola C, Wieczorek PM. Efficacy of low-dose bupivacaine in spinal anaesthesia for Caesarean delivery: systematic review and meta-analysis. *British journal of anaesthesia*. 2011 Sep 1;107(3):308-18.
38. Cenkowski MJ, Maguire D, Kowalski S, Al Gurashi FA, Funk D. Hemodynamic effects of low-dose bupivacaine spinal anesthesia for cesarean section: A randomized controlled trial. *Saudi journal of anaesthesia*. 2019 Jul 1;13(3):208-14.
39. Kumar S, Santha N. Low dose and the conventional dose of 0.5% hyperbaric bupivacaine produce comparable outcomes in the lower segment caesarean section. An observational study. *Annals of African medicine*. 2022 Oct 1;21(4):390-4.
40. Dyer RA, Joubert IA. Low-dose spinal anaesthesia for caesarean section. *Current Opinion in Anesthesiology*. 2004 Aug 1;17(4):301-8.
41. Venkata HG, Pasupuleti S, Pabba UG, Porika S, Talari G. A randomized controlled prospective study comparing a low dose bupivacaine and fentanyl mixture to a conventional dose of hyperbaric bupivacaine for cesarean section. *Saudi journal of anaesthesia*. 2015 Apr 1;9(2):122-7.
42. Fan SZ, Susetio L, Wang YP, Cheng YJ, Liu CC. Low dose of intrathecal hyperbaric bupivacaine combined with epidural lidocaine for cesarean section—a balance block technique. *Anesthesia & Analgesia*. 1994 Mar 1;78(3):474-7.
43. Ben-David B, Miller G, Gavriel R, Gurevitch A. Low-dose bupivacaine-fentanyl spinal anesthesia for cesarean delivery. *Regional Anesthesia & Pain Medicine*. 2000 May 1;25(3):235-9.
44. Sun Y, Xu Y, Wang GN. Comparative evaluation of intrathecal bupivacaine alone, bupivacaine-fentanyl, and bupivacaine-dexmedetomidine in caesarean section. *Drug research*. 2015 Sep;65(09):468-72.
45. Al-Awwady AN, Nassar RA. Comparison of Combined Fentanyl-Bupivacaine Versus Bupivacaine Monotherapy in Combined Spinal-Epidural Analgesia for Labor Pain Relief. *Medical Journal of Babylon*. 2025 Jun 1;22(Suppl 1):S69-74.
46. Mitra S, Kaushal H, Gupta RK. Evaluation of analgesic efficacy of intra-articular bupivacaine, bupivacaine plus fentanyl, and bupivacaine plus tramadol after arthroscopic knee surgery. *Arthroscopy: The Journal of Arthroscopic & Related Surgery*. 2011 Dec 1;27(12):1637-43.
47. Torda TA, Hann P, Mills G, De Leon G, Penman D. Comparison of extradural fentanyl, bupivacaine and two fentanyl-bupivacaine mixtures for pain relief after abdominal surgery. *British Journal of Anaesthesia*. 1995 Jan 1;74(1):35-40.
48. Cooper DW, Turner G. Patient-controlled extradural analgesia to compare bupivacaine, fentanyl and bupivacaine with fentanyl in the treatment of postoperative pain. *British journal of anaesthesia*. 1993 May 1;70(5):503-7.
49. Shah OM, Bhat KM. Comparison of the efficacy and safety of morphine and fentanyl as adjuvants to bupivacaine in providing operative anesthesia and postoperative analgesia in subumbilical surgeries using combined spinal epidural technique. *Anesthesia Essays and Researches*. 2017 Oct 1;11(4):913-20.

50. Khanna A, Saxena R, Dutta A, Ganguly N, Sood J. Comparison of ropivacaine with and without fentanyl vs bupivacaine with fentanyl for postoperative epidural analgesia in bilateral total knee replacement surgery. *Journal of Clinical Anesthesia*. 2017 Feb 1;37:7-13.
51. Tadesse MA, Alemu EA, Allene MD, Abebe MM, Alimawu AA, Kebede FS, Wondemu ES. Efficacy and safety of midazolam compared to fentanyl as adjuvants to hyperbaric bupivacaine in spinal anesthesia: a systematic review and meta-analysis of randomized controlled trials. *BMC anesthesiology*. 2025 Aug 7;25(1):397.
52. Dutta S, Sadiq A, Rana A, Qamaruddin A, Rudra S, Israr S, Zulfiqar R, Munir T. Maternal and Neonatal Outcomes of Spinal Anesthesia during an Emergency Cesarean Section in Comparison of General Anesthesia. *General Medicine*. 2024;26:2133-42.
53. Park HS, Choi WJ. Use of vasopressors to manage spinal anesthesia-induced hypotension during cesarean delivery. *Anesthesia and Pain Medicine*. 2024 Apr 30;19(2):85-93.
54. Habib AS. A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. *Anesthesia & Analgesia*. 2012 Feb 1;114(2):377-90.
55. Gori F, Pasqualucci A, Corradetti F, Milli M, Peduto VA. Maternal and neonatal outcome after cesarean section: the impact of anesthesia. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2007 Jan 1;20(1):53-7.
56. Obi V, Umeora OJ. Anesthesia for emergency cesarean section: A comparison of spinal versus general anesthesia on maternal and neonatal outcomes. *African Journal of Medical and Health Sciences*. 2018 Jan 1;17(1):31-.
57. Liu T, Wang Y, Xiao X, Chen Z, Li X, Liu C. Comparison of maternal and neonatal outcomes between general anesthesia and combined spinal-epidural anesthesia in cesarean delivery for pregnancy complicated with placenta previa. *BMC anesthesiology*. 2025 Jun 9;25(1):294.
58. Hung TY, Huang YS, Lin YC. Maternal and neonatal outcomes with the addition of intrathecal midazolam as an adjuvant to spinal anesthesia in cesarean delivery: A systematic review and meta-analysis of randomized controlled trials. *Journal of Clinical Anesthesia*. 2022 Sep 1;80:110786.
59. Anaesthesiology HF, Zahir J. Maternal and neonatal outcome after spinal versus general anaesthesia for caesarean delivery. *Ann Pak Inst Med Sci*. 2011;7(3):115-8.
60. Saygı Aİ, Özdamar Ö, Gün İ, Emirkadı H, Müngen E, Akpak YK. Comparison of maternal and fetal outcomes among patients undergoing cesarean section under general and spinal anesthesia: a randomized clinical trial. *Sao Paulo Medical Journal*. 2015 Jun;133(3):227-34.
61. Sheikh F, Ahmed M, Ommid M, Gurcoo S, Shakoor N, Nazir S, Nisa G. Comparative evaluation of low dose hyperbaric bupivacaine with or without fentanyl in spinal anaesthesia for caesarean section in patients with pregnancy induced hypertension. *Internet J Anesthesiol*. 2013;31:1-7.
62. Venkata HG, Pasupuleti S, Pabba UG, Porika S, Talari G. A randomized controlled prospective study comparing a low dose bupivacaine and fentanyl mixture to a conventional dose of hyperbaric bupivacaine for cesarean section. *Saudi Journal of Anaesthesia*. 2015 Apr-Jun;9(2):122-127.
63. Abhinav AV. A comparative study between 0.5% hyperbaric bupivacaine and 0.5% hyperbaric bupivacaine with 25 mcg fentanyl in spinal anaesthesia in obstetric patients undergoing elective LSCS. *Journal of Evolution of Medical and Dental Sciences*. 2015 Apr 2;4(27):4636-44.
64. Thakore S, Thakore N, Chatterji R, Chatterjee CS, Nanda S. Evaluating the Efficacy of Low-Dose Hyperbaric Levobupivacaine (0.5%) Versus Hyperbaric Bupivacaine (0.5%) Along with Fentanyl for Subarachnoid Block in Patients Undergoing Medical Termination of Pregnancy and Sterilization: A Prospective, Randomized Study. *Journal of Obstetric Anaesthesia and Critical Care*. 2018 Jul-Dec;8(2):90-95.
65. Baheti SN, Gulia T, Solanki SP. A prospective study comparing a low dose bupivacaine and fentanyl mixture to a conventional dose of hyperbaric bupivacaine for elective lower segment Caesarean section. *International Journal*. 2021 May;4(3):629.
66. Ferrarezi WP, Braga AD, Ferreira VB, Mendes SQ, Brandão MJ, Braga FS, Carvalho VH. Spinal anesthesia for elective cesarean section. Bupivacaine associated with different doses of fentanyl: randomized clinical trial. *Brazilian Journal of Anesthesiology*. 2021 Oct 25;71(6):642-8.
67. Kumar S, Santha N. Low dose and the conventional dose of 0.5% hyperbaric bupivacaine produce comparable outcomes in the lower segment caesarean section. An observational study. *Ann Afr Med*. 2022 Oct-Dec;21(4):390-394.

68. Moustafa MM, Ali MS, McCaul C, Abbas MS. Comparison of sequential and mixture injections of opioids and hyperbaric bupivacaine for subarachnoid block for lower segment caesarean section: a randomised controlled study. *Irish Journal of Medical Science* (1971-). 2024 Aug;193(4):1977-83.
69. Radhi SJ, Flaifel HA, Humaddi HK. A Comparative Study of Three Different Intrathecal Bupivacaine Doses During Combined Spinal Epidural Anesthesia for Cesarean Delivery. *Journal Of Medicine And Surgery*. 2025 Aug 24;4(8):37-47.
70. Sun LH, Jiao CC, Wu H, Dai AG, Chen Q, Jin L, Chen XP, Qian XW, Kee WD, Chen XZ. Intrathecal bupivacaine versus bupivacaine plus fentanyl for anaesthesia for Caesarean delivery: a randomised double-blind noninferiority trial. *British Journal of Anaesthesia*. 2025 Nov 13.